PL344745A1 - Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid - Google Patents

Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid

Info

Publication number
PL344745A1
PL344745A1 PL99344745A PL34474599A PL344745A1 PL 344745 A1 PL344745 A1 PL 344745A1 PL 99344745 A PL99344745 A PL 99344745A PL 34474599 A PL34474599 A PL 34474599A PL 344745 A1 PL344745 A1 PL 344745A1
Authority
PL
Poland
Prior art keywords
hyaluronic acid
pharmaceutical formulation
formulation containing
microbial enzyme
digests
Prior art date
Application number
PL99344745A
Inventor
Norbert Presselt
Peter-Juergen Mueller
Joerg-Hermann Ozegowski
Albert Haertl
Gundela Peschel
Original Assignee
Id Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998160542 external-priority patent/DE19860542A1/en
Priority claimed from DE1998160541 external-priority patent/DE19860541A1/en
Application filed by Id Pharma Gmbh filed Critical Id Pharma Gmbh
Publication of PL344745A1 publication Critical patent/PL344745A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02001—Hyaluronate lyase (4.2.2.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL99344745A 1998-12-23 1999-12-22 Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid PL344745A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1998160542 DE19860542A1 (en) 1998-12-23 1998-12-23 An enzyme fragment with hyaluronate lyase activity is derived from streptococci and used for medical applications
DE1998160541 DE19860541A1 (en) 1998-12-23 1998-12-23 Composition for the treatment of vascular disease comprises holozyme with hyaluronate lyase activity from microbial origin
PCT/DE1999/004108 WO2000039290A2 (en) 1998-12-23 1999-12-22 Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid

Publications (1)

Publication Number Publication Date
PL344745A1 true PL344745A1 (en) 2001-11-19

Family

ID=26051101

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99344745A PL344745A1 (en) 1998-12-23 1999-12-22 Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid

Country Status (10)

Country Link
EP (1) EP1056839A1 (en)
JP (1) JP2002533473A (en)
KR (1) KR20010041235A (en)
AU (1) AU3032400A (en)
CA (1) CA2318356A1 (en)
DE (1) DE19982882D2 (en)
HU (1) HUP0103660A2 (en)
IL (1) IL138051A0 (en)
PL (1) PL344745A1 (en)
WO (1) WO2000039290A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963538A1 (en) * 1999-12-22 2001-07-05 Univ Schiller Jena Use of an enzyme to improve tissue absorption of drugs
DE10103271A1 (en) * 2001-01-23 2002-07-25 Knoell Hans Forschung Ev Pharmaceutical formulation containing hyaluronatlyase, useful for softening of connective tissue in medical and cosmetic treatment, especially in shape correction
SG177008A1 (en) 2003-03-05 2012-01-30 Halozyme Inc Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
AU2003239763A1 (en) * 2003-05-27 2005-01-04 Friedrich-Schiller- Universität Jena Hyaluronate lyase-containing agent for treating acute myocardial infarction or symptoms thereof and for the treatment of postinfarction myocarditis and myocardial ischaemia
DE102007031417A1 (en) 2007-07-04 2009-01-08 Friedrich-Schiller-Universität Jena Hyaluronate lyase with a histidine tag e.g. useful in pharmaceutical formulations and medical products
KR20100094982A (en) 2007-11-13 2010-08-27 바이오-테크널러지 제너럴 (이스라엘) 리미티드 Dilute filtration sterilization process for viscoelastic biopolymers
EP3037529B1 (en) 2008-12-09 2019-03-27 Halozyme, Inc. Extended soluble ph20 polypeptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1120298A (en) * 1966-07-11 1968-07-17 Biorex Laboratories Ltd Stabilised enzymes
US3708575A (en) * 1970-05-13 1973-01-02 Biorex Laboratories Ltd Method for the treatment of atherosclerosis employing glucuronoglycos-aminoglycan-hyaluronate-lyase
US3728223A (en) * 1971-10-08 1973-04-17 Amano Pharma Co Ltd Production of hyaluronidase from a strain of streptomyces
EP1140199B1 (en) * 1998-12-23 2003-07-23 Esparma GmbH Hyaluronate lyase used for promoting penetration in topical agents

Also Published As

Publication number Publication date
IL138051A0 (en) 2001-10-31
EP1056839A1 (en) 2000-12-06
WO2000039290A8 (en) 2000-10-19
AU3032400A (en) 2000-07-31
JP2002533473A (en) 2002-10-08
CA2318356A1 (en) 2000-07-06
WO2000039290A3 (en) 2001-03-08
WO2000039290A2 (en) 2000-07-06
KR20010041235A (en) 2001-05-15
HUP0103660A2 (en) 2002-01-28
DE19982882D2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
AU6740298A (en) Pharmaceutical composition
AU3192700A (en) Medicinal compositions
AU1878601A (en) Enzyme
AU4823800A (en) Modular display system
AU3556400A (en) Pharmaceutical compositions
AU1574900A (en) Pharmaceutical compositions containing insulin
AU2005300A (en) Medicinal compositions
AU1887401A (en) Medicinal composition
AU4328800A (en) Pharmaceutical formulation
AU8107998A (en) Pharmaceutical compositions
AU1564501A (en) Display system
PL344745A1 (en) Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid
AU3677100A (en) Alpha-glycated amino acid releasing enzyme
AU6949200A (en) Human hydrolytic enzymes
AU6460400A (en) Pharmaceutical compositions
AU9343098A (en) Pharmaceutical composition
AU4977300A (en) Pharmaceutical formulations
AU1385801A (en) Pharmaceutical formulations
AU6460200A (en) Pharmaceutical compositions
AUPP332898A0 (en) Pharmaceutical composition
AU3041500A (en) Dermatological compositions containing tannic acid and a microbial proliferationinhibitor
AU3839900A (en) Pharmaceutical formulation
AU6460100A (en) Pharmaceutical compositions
AU6460300A (en) Pharmaceutical compositions
AU4914400A (en) Novel pharmaceutical composition

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)